User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

9831

Interactions with Platform & by Email *

INTERACTIONS

1376

Unique # Participated *

PARTICIPANTS

295

Responses Validated *

VALIDATIONS

56

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
   Atrial fibrillation: A Prelude.....II-1
Market Outlook.....II-1
The Market Opportunity.....II-1
1$100
   Table 1: Population Growth (60+ age group) over the Period 2009-2013¬ (includes corresponding Graph/Chart).....II-21$300
   Side-Effects and Ineffectiveness Mar Current AF Drug Therapy Option.....II-3
Non-Pharmacotherapy to Exhibit Strong Growth.....II-3
Table 2: Global Atrial Fibrillation Market (2007): Annual Atrial Fibrillation Procedures by Region/ Country - US, Europe, and Rest of World (includes corresponding Graph/Chart).....II-3
1$300
   Ablation Catheters to Bolster Market Growth for AF Devices.....II-4
Increased Popularity of Ablation Catheters Drive Product Developments.....II-4
Clinical Trials and Technology Enhancements Propel AF Ablation Market.....II-4
Convenience and Safety Brings Novel Anticoagulants to the Forefront.....II-4
1$100
   Diagnostic EP Catheters Poised for Robust Growth.....II-5
Mapping Features in Diagnostic EP Catheters Contribute to Growth.....II-5
Balloon Catheters: Most Effective Treatment for Paroxysmal AF.....II-5
New Technologies in Ablation.....II-5
2$125
   Treatment Objectives for Atrial Fibrillation.....II-7
Existing Treatment Protocols: Pharmacological and Interventional Approach.....II-7
1$100
   Pharmacological Treatment.....II-8
Rate and Rhythm Control.....II-8
Rate Control.....II-8
Popular Drugs Used for Rate Control.....II-8
1$100
   Rhythm Control.....II-9
Popular Drugs Used for Rhythm Control.....II-9
1$100
   List of Different Types of Antiarrhythmic Drugs.....II-10
Stroke Prevention through Drugs.....II-10
Anticoagulation.....II-10
1$100
   Cardioversion.....II-11
Chemical Cardioversion.....II-11
1$100
   Electrical Cardioversion.....II-12 1$100
   Table 3: Global Atrial Fibrillation Market (2007): Percentage Response Rate of Most Effective Therapy for Treatment of Atrial Fibrillation by Drugs - Diltiazem (Cardizem), Electrical Cardioversion, Amiodarone (Cordarone), Propranolol, Ibutilide (Corvert) and Others (includes corresponding Graph/Chart).....II-13
Select Anti-Arrhythmic drugs.....II-13
Multaq® (dronedarone).....II-13
Amiodarone.....II-13
1$300
   Digoxin (Lanoxin).....II-141$100
   Non-Pharmacological Treatment.....II-15
Ablate and Pace Technique.....II-15
Left Atrial Appendage Closure – Alternative to Anticoagulation.....II-15
Catheter Ablation.....II-15
1$100
   Techniques of Catheter Ablation.....II-161$100
   Patient Selection.....II-17
Results of AF Ablation.....II-17
Complications.....II-17
1$100
   Post-Ablation Considerations.....II-18
Pulmonary Vein Isolation.....II-18
1$100
   Cox Maze.....II-19
Minimally-Invasive Maze Techniques.....II-19
1$100
   Standard Surgical Ablation.....II-20
HIFU Surgical Ablation.....II-20
Other Recent Approaches to Ablation.....II-20
1$100
   Europe.....II-21
Physician’s Confidence and New Product Launches Fuel Growth.....II-21
Inorganic Growth to Keep Alive European Electrophysiology Market.....II-21
Technological Sophistication to Drive Growth in European EP Ablation Catheters
  Market.....II-21
1$100
   Cost Cutting Measures Pull Back European EP Ablation Catheters Market.....II-22
Technological Breakthroughs Augur Growth in European Cardiac Rhythm
  Management.....II-22
United States.....II-22
Key Statistical Findings.....II-22
Table 4: US Atrial Fibrillation Prevalence for the Period 2010-2050 (includes corresponding Graph/Chart).....II-22
1$300
   Table 5: US Atrial Fibrillation Market Occurrence by Age and Gender: 2006 (includes corresponding Graph/Chart).....II-23

Table 6: US Atrial Fibrillation Market (2006): Percentage Utilization of Medical Service by Patients with AF (includes corresponding Graph/Chart).....II-23
1$300
   Table 7: US Atrial Fibrillation Market (2006): Average Annual Direct-Per-Patient Costs Incurred by Patients with AF (includes corresponding Graph/Chart).....II-24

Table 8: US Atrial Fibrillation Therapeutic Market (2007): Percentage Breakdown of Revenues by Category - Amiodarone, Sotalol, Propafenone, Fiecainide, and Others (includes corresponding Graph/Chart).....II-24

Table 9: US Healthcare Spending (in US$ trillion): 2008 and 2017.....II-24

Table 10: US ICD Market Share (2010): Percentage Breakdown of Market Share by Players - Medtronic, Boston Scientific, St. Jude Medical, and Others (includes corresponding Graph/Chart).....II-24
1$300
   US Electrophysiology Ablation Catheters Market: An Overview.....II-25
Atrial Fibrillation Procedures on Growth Trajectory.....II-25
Manual Steering Procedures Score over Robotic and Remote Magnetic Guidance
  Systems.....II-25
China.....II-25
Canada.....II-25
1$100
   Introduction.....II-26
What is Atrial Fibrillation?.....II-26
History of AF.....II-26
Risk Factors.....II-26
Controllable Risk Factors.....II-26
1$100
   Non-Controllable Risk Factors.....II-27
Steps to Reduce Risk Factors and Treat Underlying Reasons.....II-27
1$100
   Preventive Measures.....II-28
Causes of Atrial Fibrillation.....II-28
Symptoms of Atrial Fibrillation.....II-28
1$100
   Consequences of Atrial Fibrillation.....II-29
Morbidity and Mortality Consequences.....II-29
AF Significantly Impacts Quality of Life.....II-29
Impact on Healthcare System.....II-29
Patterns of Atrial Fibrillation.....II-29
First Detected AF.....II-29
Paroxysmal Atrial Fibrillation.....II-29
Persistent Atrial Fibrillation.....II-29
1$100
   Chronic or Permanent Atrial Fibrillation.....II-30
Postoperative Atrial Fibrillation.....II-30
Classification of Atrial Fibrillation.....II-30
Lone Atrial Fibrillation (LAF).....II-30
Non-valvular AF.....II-30
Secondary AF.....II-30
Identification of Atrial Fibrillation.....II-30
1$100
   Diagnosis or Evaluation of AF.....II-31
Minimal Evaluation Methods.....II-31
Routine Blood Diagnosis.....II-31
Electrocardiogram.....II-31
1$100
   Tilt-Table Test.....II-32
Physical Examination and History.....II-32
Extended Evaluation Methods.....II-32
Event Recording.....II-32
Echocardiography.....II-32
Trans-esophageal Echocardiogram.....II-32
1$100
   Chest X-Ray.....II-33
Electrophysiology Study.....II-33
Exercise-Stress Testing.....II-33
1$100
   Ambulatory Holter Monitoring.....II-34
Cardiac Mapping.....II-34
1$100
   Effects of Atrial Fibrillation.....II-35
Progressive Atria Fibrosis.....II-35
Thromboembolism.....II-35
Research on Atrial Fibrillation.....II-35
2$125
   St. Jude Announces IRASE AF Clinical Trial to Evaluate Cardiac Ablation Catheter System
  for Treating AF.....II-37
Biosense Webster Supports Landmark Global CABANA Clinical Trial for Atrial
  Fibrillation.....II-37
1$100
   Cardiome Pharma Announces Completion of European Comparator Study.....II-38
Mayo Clinic Receives Grant to Study Treatment for Atrial Fibrillation.....II-38
Medtronic Completes STOP-AF Trial of Medtronic Arctic Front® CryoAblation Catheter
  System.....II-38
1$100
   The Mount Sinai Medical Center Uses Atrial Ablation Catheter of CardioFocus.....II-39
US Cardiologists Carry Out First 3D Imaging of Complex Cardiac Anatomy.....II-39
Warfarin Therapy Found Effective for Atrial Fibrillation.....II-39
1$100
   ABLATE Clinical Trial of AtriCure for Evaluation of Isolator Synergy™ Bipolar Ablation
  System.....II-40
Ablation Frontiers’ Atrial Fibrillation Cardiac Ablation Technology Evaluated.....II-40
1$100
   Montreal Heart Institute Organizes Global Clinical Trial.....II-411$100
   deCODE Genetics Highlights Clinical Utility of deCODE AFTM.....II-421$100
   Boehringer Ingelheim Announces Enrollment for RE-LY Trial.....II-431$100
   RF Ablation Generator and Catheter Proves to be Successful in Atrial
  Fibrillation.....II-44
ATI-2042 Proves Successful in Atrial Fibrillation.....II-44
1$100
   NaviStar® ThermoCool Catheter Proves Better Treatment Alternative than AAD
  Therapy.....II-45
1$100
   St. Jude Medical's Anthem RF CRT-P and Accent RF Pacemaker Receive FDA
  Approval.....II-46
Sorin Group Acquires Regulatory Approval to Market Pacemakers in Japan.....II-46
NaviStar Catheter Receives FDA Approval for Atrial Fibrillation.....II-46
1$100
   Multaq Receives EU Approval for Atrial Fibrillation.....II-47
Multaq Receives Approval from Health Canada for Atrial Fibrillation.....II-47
1$100
   Sanofi-aventis Receives FDA Approval for Multaq 400 mg Tablets.....II-48
St. Jude Medical's Current Accel and AnalyST Accel ICDs Receive CE Mark.....II-48
Biosense Webster Manufactured Devices Receive FDA Approval.....II-48
Cardima Obtains CE Mark Approval for Surgical Ablation Probe with Stabilization
  Sheath.....II-48
1$100
   St. Jude Receives CE Mark Approval for SJM Confirm™ ICM.....II-49
CV Therapeutics Manufactured Ranexa Obtains FDA Approval.....II-49
1$100
   dosense and Biotronik Sign Global Distribution Agreement.....II-50
Merck Acquires Commercial Rights for Betrixaban.....II-50
Erasmus University Medical Centre and CLT Israel Sign Joint Venture Agreement.....II-50
1$100
   Gilead Sciences to Take Over CV Therapeutics.....II-51
BMS, Teijin Pharma and Nissan Chemical Industries form Worldwide Collaboration.....II-51
Medtronic Acquires Ablation Frontiers.....II-51
Merck Signs Collaboration Agreement with Cardiome.....II-51
1$100
   Royal Philips Collaborates with Bard to Co-Develop Clinical Tools for
  Arrhythmias.....II-52
1$100
   Medtronic Acquires CryoCath Technologies.....II-53
Heritage Pharma and Ipca Laboratories Enter into Strategic Alliance.....II-53
Nissan Chemical to Seek Overseas Licensee for Atrial Fibrillation Drug.....II-53
Boston Scientific Acquires CryoCor.....II-53
St. Jude Signs Merger Agreement with MediGuide.....II-53
1$100
   St. Jude Medical Acquires EP MedSystems.....II-54
Cardima Signs Marketing Contract with On-X Life Technologies.....II-54
Angiotech Pharmaceuticals Signs Licensing Agreement with Symphony Medical.....II-54
1$100
   AtriCure Acquires Frigitronics CCS-200 Product Range from Cooper Surgical.....II-551$100
   Sorin Introduces Implant of Advanced Cardiac Resynchronization Therapy
  Defibrillator.....II-56
Sanofi-aventis Launches Multaq in the US.....II-56
Medtronic Launches Insertable Cardiac Monitor in US.....II-56
1$100
   St. Jude Medical Launches Medical Devices for Heart Rhythm Disorders.....II-57
eCardio Diagnostics Launches AFISTM Informatics Solution.....II-57
1$100
   BIOTRONIK Unveils Lumax 540 Devices for Cardiac Rhythm Management in the US.....II-581$100
   CardioNet Launches Improved CardioNet AF Management Program.....II-59
LifeWatch Launches First Commercial LifeWatch Atrial Fibrillation Patient Care
  Program.....II-59
CryoCath Technologies Launches Arctic Front in Belgium, Spain and Italy.....II-59
ATS Medical Introduces ATS CryoMaze Clamp for Surgical Ablation.....II-59
2$125
   AtriCure, Inc. (US).....II-61
Baxter International, Inc. (US).....II-61
Becton, Dickinson & Company (US).....II-61
1$100
   Biosense Webster, Inc. (US).....II-62
Boston Scientific Corp. (US).....II-62
1$100
   Cardiome Pharma Corp. (Canada).....II-63
C.R. Bard, Inc. (US).....II-63
Cardima, Inc. (US).....II-63
1$100
   Endosense SA (Switzerland).....II-64
Medtronic, Inc. (US).....II-64
Sanofi-Aventis (France).....II-64
1$100
   Sorin SpA (Italy).....II-65
Spectrasonics, Inc. (US).....II-65
St. Jude Medical, Inc. (US).....II-65
1$100
   Zimmer Holdings, Inc. (US).....II-661$100
   Table 11: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Segment - Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-671$300
   Table 12: World 10-Year Perspective for Atrial Fibrillation by Segment - Percentage Breakdown of Dollar Sales by Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories and Diagnostics for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-681$300
   Table 13: Atrial Fibrillation Therapies Worldwide: Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-691$300
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com